{"id":"ror1","name":"ROR1","symbol":"ROR1","route":"/targets/ror1/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10256","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185483","uniprot":"https://www.uniprot.org/uniprotkb/Q01973/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q01973","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4665585","open-targets":"https://platform.opentargets.org/target/ENSG00000185483","civic":"https://civicdb.org/genes/4919/summary","oncokb":"https://www.oncokb.org/gene/ROR1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ROR1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=ROR1","depmap":"https://depmap.org/portal/gene/ROR1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000185483-ROR1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/4919","omim":"https://www.omim.org/entry/602336"}],"products":[{"id":"zilovertamab-vedotin","name":"Zilovertamab vedotin","status":"phase-3","modality":"ADC","route":"/drugs/zilovertamab-vedotin/"}],"trials":[{"id":"nct06717347","name":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi","nct":"NCT06717347","phase":"3","status":"recruiting"},{"id":"waveline-003","name":"waveLINE-003","nct":"NCT05139017","phase":"2/3","status":"recruiting"},{"id":"nct06890884","name":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","nct":"NCT06890884","phase":"2","status":"recruiting"},{"id":"nct05458297","name":"A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-","nct":"NCT05458297","phase":"2","status":"active"},{"id":"nct05406401","name":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","nct":"NCT05406401","phase":"2","status":"active"},{"id":"nct05562830","name":"A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)","nct":"NCT05562830","phase":"1/2","status":"recruiting"},{"id":"nct07510802","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC","nct":"NCT07510802","phase":"1/2","status":"recruiting"},{"id":"nct06395103","name":"Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)","nct":"NCT06395103","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["merck"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}